Last Updated: November 22, 2026

Futibatinib - Generic Drug Details

« Back to Dashboard


What are the generic sources for futibatinib and what is the scope of patent protection?

Futibatinib is the generic ingredient in one branded drug marketed by Taiho Oncology and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for futibatinib
International Patents:79
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Clinical Trials: 15
What excipients (inactive ingredients) are in futibatinib?futibatinib excipients list
DailyMed Link:futibatinib at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for futibatinib
Generic Entry Date for futibatinib*:
Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA HARBORING FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) GENE FUSIONS OR OTHER REARRANGEMENTS

Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for futibatinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Institut fr Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPHASE2
Universittsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. MhlerPHASE2
Yuanquan YangPHASE2

See all futibatinib clinical trials

US Patents and Regulatory Information for futibatinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taiho Oncology LYTGOBI futibatinib TABLET;ORAL 214801-002 Jul 28, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Taiho Oncology LYTGOBI futibatinib TABLET;ORAL 214801-002 Jul 28, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Taiho Oncology LYTGOBI futibatinib TABLET;ORAL 214801-002 Jul 28, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Taiho Oncology LYTGOBI futibatinib TABLET;ORAL 214801-002 Jul 28, 2025 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Taiho Oncology LYTGOBI futibatinib TABLET;ORAL 214801-001 Sep 30, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Taiho Oncology LYTGOBI futibatinib TABLET;ORAL 214801-001 Sep 30, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Taiho Oncology LYTGOBI futibatinib TABLET;ORAL 214801-001 Sep 30, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for futibatinib

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Taiho Pharma Netherlands B.V. Lytgobi futibatinib EMEA/H/C/005627Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Authorised no no no 2023-07-04
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for futibatinib

Country Patent Number Title Estimated Expiration
Australia 2016240841 ⤷  Start Trial
Brazil 112017019809 ⤷  Start Trial
Canada 2980888 ⤷  Start Trial
China 107406455 ⤷  Start Trial
China 111393446 ⤷  Start Trial
Denmark 3279202 ⤷  Start Trial
European Patent Office 3279202 CRISTAL D'UN COMPOSÉ D'ALCYNYLE DE BENZÈNE 3,5-DISUBSTITUÉ (CRYSTAL OF 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for futibatinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2657233 42/2023 Austria ⤷  Start Trial PRODUCT NAME: FUTIBATINIB ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1741 (MITTEILUNG) 20230706
2657233 2390034-3 Sweden ⤷  Start Trial PRODUCT NAME: FUTIBATINIB OR A SALT THEREOF; REG. NO/DATE: EU/1/23/1741 20230706
2657233 C202330047 Spain ⤷  Start Trial PRODUCT NAME: FUTIBATINIB O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1741; DATE OF AUTHORISATION: 20230704; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1741; DATE OF FIRST AUTHORISATION IN EEA: 20230704
2657233 C20230038 Finland ⤷  Start Trial
2657233 CA 2023 00036 Denmark ⤷  Start Trial PRODUCT NAME: FUTIBATINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/23/1741 20230706
2657233 CR 2023 00036 Denmark ⤷  Start Trial PRODUCT NAME: FUTIBATINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/23/1741 20230706
2657233 2023C/548 Belgium ⤷  Start Trial PRODUCT NAME: FUTIBATINIB OF EEN ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1741 20230706
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.